Clinical Studies Sponsored by Bavarian Nordic

Clinical Studies where

Trial Sponsor

Name	NCT Number	Health Conditions in Trial	Clinical Trial Start Date	Study Completion Date	Clinical Trial Study Type
‌ Single-Blind, Controlled Safety and Immunogenicity Study of Recombinant MVA Virus to Treat HIV Infection	NCT00390078		2007	2009	Interventional
‌ PROSTVAC®-VF/TRICOM™ Vaccine for the Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy	NCT00078585	Prostate cancer	2003	2009	Interventional
‌ A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Metastatic Breast Cancer	NCT00485277	‌ Breast Cancer	2007	2010	Interventional
‌ Study on Safety, Tolerability and Immunogenicity of an MVA Vaccine Administered to Healthy Subjects	NCT00189943	Smallpox	2001	2003	Interventional
‌ Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 Years	NCT00891007	Measles	2009	2010	Interventional
‌ Take Rate, Immunogenicity and Safety of Elstree-BN Smallpox Vaccine in Healthy Vaccinia-Naive Subjects	NCT00189969	Smallpox	2003	2006	Interventional
‌ An Evaluation of Immunogenicity and Safety of Two Doses of MVA-nef vs. MVA-BN in HIV-1 Infected Patients	NCT00189930		2005	2006	Interventional
‌ Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients	NCT00189904		2005		Interventional
‌ Safety and Tolerability Trial (MVA-BN-Brachyury/FPV-Brachyury)	NCT03349983		January 8, 2018	June 13, 2020	Interventional
‌ Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection	NCT02038881	Smallpox	April 28, 2014	May 10, 2017	Interventional
‌ VAXCHORA Pediatric Study to Assess Safety and Immunogenicity	NCT03220737		July 21, 2017	March 6, 2020	Interventional
‌ Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years	NCT05349617		May 12, 2022	August 8, 2023	Interventional
‌ A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects	NCT01668537	Smallpox	2013	2014	Interventional
‌ RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults	NCT02864628		2016	October 27, 2017	Interventional
‌ A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer	NCT04134312		January 8, 2020	April 6, 2021	Interventional
‌ A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000®	NCT01913353		2015	2017	Interventional
‌ A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects	NCT01144637	Smallpox	2013	2014	Interventional
‌ Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients	NCT00316589		2006	2009	Interventional
‌ RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults	NCT02873286		2016	2018	Interventional
‌ Special Access Program IMVAMUNE®	NCT03472014	Vaccination	April 22, 2010	November 14, 2014	Interventional
‌ A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults	NCT02094586	Cholera	2014	2015	Interventional
‌ A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer	NCT02840994		2016	2020	Interventional
‌ A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis	NCT00316602	Atopic dermatitis	2006	2010	Interventional
‌ A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects	NCT00857493	Smallpox	2009	2010	Interventional
‌ Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine	NCT02419391		2015	2016	Interventional

Results per page:

44 results

0 selected

44 results

0 selected